The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Abbvie Inc shares valued at $13,231,264 were purchased by Richard A. Gonzalez on Aug 22 ’25. At $210.84 per share, Richard A. Gonzalez acquired 62,755 shares.
Also, Richard A. Gonzalez purchased 90,000 shares, netting a total of over 18,993,948 in proceeds.
Before that, SALEKI-GERHARDT AZITA had sold 42,370 shares from its account. In a trade valued at $8,407,055, the EVP, CHIEF OPERATIONS OFFICER traded Abbvie Inc shares for $198.42 each. Upon closing the transaction, the insider’s holdings decreased to 42,370 shares, worth approximately $39.34 million.
As published in a research note from Wolfe Research on January 08, 2026, Abbvie Inc [ABBV] has been rated down from an Outperform to a Peer perform. As of December 10, 2025, HSBC Securities has increased its “Hold” rating to a “Buy” for ABBV. Earlier on November 13, 2025, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for ABBV stock.
Analyzing ABBV Stock Performance
On last trading session, Abbvie Inc [NYSE: ABBV] rose 0.52% to $221.89. The stock’s lowest price that day was $217.0, but it reached a high of $223.3383 in the same session. During the last five days, there has been a drop of approximately -4.94%. Over the course of the year, Abbvie Inc shares have jumped approximately 25.55%.
Is Abbvie Inc subject to short interest?
Stocks of Abbvie Inc saw a sharp rise in short interest on 2025-12-31 jumping by 1.5 million shares to 19.71 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 18.21 million shares. A jump of 7.59% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.87 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.87.
Which companies own the most shares of Abbvie Inc (ABBV)?
In terms of Abbvie Inc share price expectations, FactSet research, analysts set an average price target of 256 in the next 12 months, up nearly 15.97% from the previous closing price of $220.75. Analysts anticipate Abbvie Inc stock to reach 289 by 2026, with the lowest price target being 240. In spite of this, 27 analysts ranked Abbvie Inc stock as Buy at the end of 2026. On November 04, 2025, DZ Bank assigned a price target of “a Hold” to the stock and downgraded coverage with a $237.
